Doutoramento em Biologia / Instituto Superior de Agronomia. Universidade de LisboaPrevious reports revealed a novel MMP-2 and -9 inhibitor in Lupinus albus seeds, named deflamin, with a strong potential as a nutraceutical for inflammatory bowel diseases (IBDs). In the present work our goal was 1) to better understand deflamin’s mode of action and 2) to produce an effective delivery system for it to be incorporated in IBD functional diets.
Deflamin was found to be an oligomer comprising similar fragments from δ-conglutin and β-conglutin. It inhibited MMP-2 and -9 activities but not their gene expression and presented no cytotoxic effects. In vivo, it effectively reduced gelatinases activity in situ, hence minimizing the risk of secondary effects.
Based on a previous patented method we were able to develop a lupin protein concentrate (LPC) which was used as an additive to cookies (10g/100g dough). Sweet and savory, as well as different flours (wheat, rice, buckwheat, oat, kamut and spelt) were tested. Overall, the LPC was found to improve the organoleptic and physical properties of the cookies. The biochemical compositions of all cookies with LPC presented higher protein and a golden-brown coloring. Furthermore, the aw and moisture content values suggested a high stability food product. Whilst the baking itself did not interfere with the gelatinase inhibitory activity in the cookies, the type of flour and the presence of sugar did, suggesting that the presence of carbohydrates can interfere with deflamin.
Our final goal was tested the efficacy of the LPC in vivo, either alone or as added to cookies using two different types of colitis. Results confirmed that the LPC alone was effective against TNBS-induced colitis, in a dose dependent-manner, reducing more than 50% the DAI scores and inhibiting MMP-9 activity. When added to cookies, the LPC induced a significant protective effect against acetic acid-induced colitis, reducing lesion, oxidative stress and DNA damage levels.
Overall, deflamin was shown to be an efficient and safe way to reduce IBDs symptoms, without prompting secondary effects. The developed LPC was found to be effective as a delivery system for deflamin and besides its activity towards MMP-9, the LPC further added a higher nutritional and antioxidant value to the already potential health benefits of deflamin. These findings can open new perspectives and novel approaches to tackle IBDS via functional diets.N/
